D.Western Therapeutics Institute (6DW) Stock Statistics & Valuation Metrics
Total Valuation
D.Western Therapeutics Institute has a market cap or net worth of EUR 19.28M. The enterprise value is EUR 3.25B.
- Market Cap
- EUR 19.28M
- Enterprise Value
- EUR 3.25B
Share Statistics
D.Western Therapeutics Institute has 57,599,410 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 57,599,410
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
D.Western Therapeutics Institute’s return on equity (ROE) is -0.44 and return on invested capital (ROIC) is -30.02%.
- Return on Equity (ROE)
- -0.44
- Return on Assets (ROA)
- -0.29
- Return on Invested Capital (ROIC)
- -30.02%
- Return on Capital Employed (ROCE)
- -0.32
- Revenue Per Employee
- 20.40M
- Profits Per Employee
- -33.27M
- Employee Count
- 19
- Asset Turnover
- 0.18
- Inventory Turnover
- 0.99
Valuation Ratios
The current PE Ratio of D.Western Therapeutics Institute is -4.96. D.Western Therapeutics Institute’s PEG ratio is -0.07.
- PE Ratio
- -4.96
- PS Ratio
- 13.73
- PB Ratio
- 2.41
- Price to FCF
- 0.00
- Price to Operating Cash Flow
- 0.00
- PEG Ratio
- -0.07
Income Statement
In the last 12 months, D.Western Therapeutics Institute had revenue of 387.62M and earned -632.09M in profits. Earnings per share was -13.19.
- Revenue
- 387.62M
- Gross Profit
- 301.24M
- Operating Income
- -619.87M
- Pretax Income
- -630.49M
- Net Income
- -632.09M
- EBITDA
- -572.35M
- Earnings Per Share (EPS)
- -13.19
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0 billion.
- Operating Cash Flow
- 0
- Free Cash Flow
- 0
- Free Cash Flow per Share
- 0.00
Dividends & Yields
D.Western Therapeutics Institute pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.00%
- Earnings Yield
- -18.83%
Stock Price Statistics
- Beta
- -0.49
- 52-Week Price Change
- -46.67%
- 50-Day Moving Average
- 0.37
- 200-Day Moving Average
- 0.41
- Relative Strength Index (RSI)
- 28.70
- Average Volume (3m)
- ―
Important Dates
D.Western Therapeutics Institute upcoming earnings date is Nov 12, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
D.Western Therapeutics Institute as a current ratio of 9.91, with Debt / Equity ratio of 42.16%
- Current Ratio
- 9.91
- Quick Ratio
- 9.48
- Debt to Market Cap
- 0.13
- Net Debt to EBITDA
- 1.93
- Interest Coverage Ratio
- -70.32
Taxes
In the past 12 months, D.Western Therapeutics Institute has paid 1.59M in taxes.
- Income Tax
- 1.59M
- Effective Tax Rate
- -0.00
Enterprise Valuation
D.Western Therapeutics Institute EV to EBITDA ratio is -3.99, with an EV/FCF ratio of 0.00.
- EV to Sales
- 9.69
- EV to EBITDA
- -3.99
- EV to Free Cash Flow
- 0.00
- EV to Operating Cash Flow
- 0.00
Balance Sheet
D.Western Therapeutics Institute has EUR 1.54B in cash and marketable securities with EUR 594.17M in debt, giving a net cash position of EUR 945.66M billion.
- Cash & Marketable Securities
- EUR 1.54B
- Total Debt
- EUR 594.17M
- Net Cash
- EUR 945.66M
- Net Cash Per Share
- EUR 16.42
- Tangible Book Value Per Share
- EUR 24.12
Margins
Gross margin is 80.49%, with operating margin of -252.02%, and net profit margin of -257.89%.
- Gross Margin
- 80.49%
- Operating Margin
- -252.02%
- Pretax Margin
- -257.24%
- Net Profit Margin
- -257.89%
- EBITDA Margin
- -242.74%
- EBIT Margin
- -253.60%
Analyst Forecast
The average price target for D.Western Therapeutics Institute is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -45.81%
- EPS Growth Forecast
- 59.30%
